Smith William T, Ferguson T Bruce, Ryan Thomas, Landolfo Carolyn K, Peterson Eric D
Duke University Medical Center, Durham, North Carolina, USA.
J Am Coll Cardiol. 2004 Sep 15;44(6):1241-7. doi: 10.1016/j.jacc.2004.06.031.
This study utilizes Markov decision analysis to assess the relative benefits of prophylactic aortic valve replacement (AVR) at the time of coronary artery bypass graft surgery (CABG). Multiple sensitivity analyses were also performed to determine the variables that most profoundly affect outcome.
The decision to perform CABG or concomitant CABG and AVR (CABG/AVR) in asymptomatic patients who need CABG surgery but have mild to moderate aortic stenosis (AS) is not clear-cut.
We performed Markov decision analysis comparing long-term, quality-adjusted life outcomes of patients with mild to moderate AS undergoing CABG versus CABG/AVR. Age-specific morbidity and mortality risks with CABG, CABG/AVR, and AVR after a prior CABG were based on the Society of Thoracic Surgeons national database (n = 1,344,100). Probabilities of progression to symptomatic AS, valve-related morbidity, and age-adjusted mortality rates were obtained from available published reports.
For average AS progression, the decision to replace the aortic valve at the time of elective CABG should be based on patient age and severity of AS measured by echocardiography. For patients under age 70 years, an AVR for mild AS is preferred if the peak valve gradient is >25 to 30 mm Hg. For older patients, the threshold increases by 1 to 2 mm Hg/year, so that an 85-year-old patient undergoing CABG should have AVR only if the gradient exceeds 50 mm Hg. The AS progression rate also influences outcomes. With slow progression (<3 mm Hg/year), CABG is favored for all patients with AS gradients <50 mm Hg; with rapid progression (>10 mm Hg/year), CABG/AVR is favored except for patients >80 years old with a valve gradient <25 mm Hg.
This study provides a decision aid for treating patients with mild to moderate AS requiring CABG surgery. Predictors of AS progression in individual patients need to be better defined.
本研究采用马尔可夫决策分析来评估在冠状动脉旁路移植术(CABG)时进行预防性主动脉瓣置换术(AVR)的相对益处。还进行了多项敏感性分析以确定对结果影响最深远的变量。
对于需要进行CABG手术但患有轻度至中度主动脉瓣狭窄(AS)的无症状患者,决定进行CABG或同期进行CABG和AVR(CABG/AVR)并不明确。
我们进行了马尔可夫决策分析,比较了接受CABG与CABG/AVR的轻度至中度AS患者的长期、质量调整生命结局。基于胸外科医师协会国家数据库(n = 1,344,100)得出CABG、CABG/AVR以及先前CABG后进行AVR的特定年龄发病率和死亡率风险。从已发表的可用报告中获取进展为有症状AS、瓣膜相关发病率以及年龄调整死亡率的概率。
对于平均AS进展情况,在择期CABG时决定是否更换主动脉瓣应基于患者年龄以及通过超声心动图测量的AS严重程度。对于70岁以下的患者,如果瓣膜峰值压差>25至30 mmHg,轻度AS患者首选AVR。对于老年患者,阈值每年增加1至2 mmHg,因此接受CABG的85岁患者仅在压差超过50 mmHg时才应进行AVR。AS进展率也会影响结局。进展缓慢(<3 mmHg/年)时,对于所有AS压差<50 mmHg的患者,CABG更受青睐;进展迅速(>10 mmHg/年)时,除了年龄>80岁且瓣膜压差<25 mmHg的患者外,CABG/AVR更受青睐。
本研究为治疗需要CABG手术的轻度至中度AS患者提供了决策辅助工具。个体患者AS进展的预测因素需要更好地明确。